Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Director · Co-Chief Executive Officer | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,827,168 |
Reported balance
After 2026-09-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-30 · Exercise / conversion · Acquired 2,817 · Balance 1,827,168 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,825,740 |
Reported balance
After 2026-09-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-30 · Tax withholding · Disposed 1,428 · Balance 1,825,740 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,849,737 |
Reported balance
After 2026-10-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Acquired 23,997 · Balance 1,849,737 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,859,453 |
Reported balance
After 2026-10-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Acquired 9,716 · Balance 1,859,453 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,842,366 |
Reported balance
After 2026-10-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-10-01 · Tax withholding · Disposed 17,087 · Balance 1,842,366 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,817 |
Reported balance
After 2026-09-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-30 · Exercise / conversion · Disposed 2,817 · Balance 2,817 F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 23,998 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 23,997 · Balance 23,998 F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 48,580 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 9,716 · Balance 48,580 F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2020 Filed Jul 7, 2020 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,060 | $84.81 | $89,896.27 |
DisclosureSEC source: 0001628280-20-010229 · wf-form4_159408074472014.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,689,532 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $84.715 to $84.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 44,299 | $83.93 | $3,718,054.94 |
DisclosureSEC source: 0001628280-20-010229 · wf-form4_159408074472014.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,690,592 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $83.68 to $84.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 9,533 | $83.48 | $795,842.49 |
DisclosureSEC source: 0001628280-20-010229 · wf-form4_159408074472014.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,734,891 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $82.68 to $83.675, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 00:12 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 54,892 | $4.18 | $229,448.56 |
DisclosureSEC source: 0001628280-20-010229 · wf-form4_159408074472014.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,744,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:46 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 55,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-20-008989 · wf-form4_159130356922729.xml · derivative · entry 11 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 765,505 Underlying: COMMON STOCK · 55,000 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 900 | $87.66 | $78,890.04 |
DisclosureSEC source: 0001628280-20-008989 · wf-form4_159130356922729.xml · nonDerivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,689,532 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $87.55 to $87.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,007 | $87.04 | $435,816.79 |
DisclosureSEC source: 0001628280-20-008989 · wf-form4_159130356922729.xml · nonDerivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,690,432 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $86.54 to $87.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 22,455 | $85.92 | $1,929,320.13 |
DisclosureSEC source: 0001628280-20-008989 · wf-form4_159130356922729.xml · nonDerivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,695,439 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $85.54 to $86.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 26,638 | $85.04 | $2,265,375.43 |
DisclosureSEC source: 0001628280-20-008989 · wf-form4_159130356922729.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,717,894 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $84.53 to $85.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:46 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 55,000 | $4.18 | $229,900.00 |
DisclosureSEC source: 0001628280-20-008989 · wf-form4_159130356922729.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,744,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 20:46 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 20,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-20-008989 · wf-form4_159130356922729.xml · derivative · entry 10 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 820,505 Underlying: COMMON STOCK · 20,000 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 20:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 10,000 | $88.25 | $882,500.00 |
DisclosureSEC source: 0001628280-20-008989 · wf-form4_159130356922729.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,689,532 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $88.00 to $88.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 20:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 10,000 | $87.02 | $870,173.00 |
DisclosureSEC source: 0001628280-20-008989 · wf-form4_159130356922729.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,699,532 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $87.00 to $87.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 20:46 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 20,000 | $4.18 | $83,600.00 |
DisclosureSEC source: 0001628280-20-008989 · wf-form4_159130356922729.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,709,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2020 Filed May 28, 2020 00:50 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantPerformance-Based Restricted Stock Units · Derivative | 1,695,574 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-008488 · wf-form4_159062700627333.xml · derivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,695,574 Underlying: COMMON STOCK · 1,695,574 shares Expires 2027-05-26 F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The performance-based restricted stock units vest, if at all, based on the Issuer's achievement of certain stock price milestones. Read SEC document |
| May 11, 2020 Filed May 11, 2020 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 6,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-20-007510 · wf-form4_158923711015273.xml · derivative · entry 17 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 840,505 Underlying: COMMON STOCK · 6,000 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| May 11, 2020 Filed May 11, 2020 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,000 | $94.01 | $470,051.50 |
DisclosureSEC source: 0001628280-20-007510 · wf-form4_158923711015273.xml · nonDerivative · entry 13 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,689,532 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $94.00 to $94.055, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 11, 2020 Filed May 11, 2020 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 59,953 | $93.41 | $5,600,197.74 |
DisclosureSEC source: 0001628280-20-007510 · wf-form4_158923711015273.xml · nonDerivative · entry 12 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,694,532 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $93.00 to $93.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 11, 2020 Filed May 11, 2020 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,200 | $92.00 | $110,400.96 |
DisclosureSEC source: 0001628280-20-007510 · wf-form4_158923711015273.xml · nonDerivative · entry 11 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,754,485 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $92.00 to $92.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 11, 2020 Filed May 11, 2020 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 60,068 | $91.34 | $5,486,575.08 |
DisclosureSEC source: 0001628280-20-007510 · wf-form4_158923711015273.xml · nonDerivative · entry 10 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,755,685 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $91.00 to $91.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 11, 2020 Filed May 11, 2020 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 73,730 | $90.40 | $6,665,103.52 |
DisclosureSEC source: 0001628280-20-007510 · wf-form4_158923711015273.xml · nonDerivative · entry 9 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,815,753 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $90.00 to $90.9902, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 11, 2020 Filed May 11, 2020 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 6,000 | $4.18 | $25,080.00 |
DisclosureSEC source: 0001628280-20-007510 · wf-form4_158923711015273.xml · nonDerivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,889,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2020 Filed May 11, 2020 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 750 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-20-007510 · wf-form4_158923711015273.xml · derivative · entry 16 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 846,505 Underlying: COMMON STOCK · 750 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| May 08, 2020 Filed May 11, 2020 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 25,049 | $90.13 | $2,257,641.32 |
DisclosureSEC source: 0001628280-20-007510 · wf-form4_158923711015273.xml · nonDerivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,883,483 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $90.00 to $90.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 08, 2020 Filed May 11, 2020 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 750 | $4.18 | $3,135.00 |
DisclosureSEC source: 0001628280-20-007510 · wf-form4_158923711015273.xml · nonDerivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,908,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2020 Filed May 11, 2020 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 1,762 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-20-007510 · wf-form4_158923711015273.xml · derivative · entry 15 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847,255 Underlying: COMMON STOCK · 1,762 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| May 07, 2020 Filed May 11, 2020 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 8,538 | $84.27 | $719,537.39 |
DisclosureSEC source: 0001628280-20-007510 · wf-form4_158923711015273.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,907,782 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $84.17 to $84.305, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 07, 2020 Filed May 11, 2020 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 41,893 | $83.73 | $3,507,901.98 |
DisclosureSEC source: 0001628280-20-007510 · wf-form4_158923711015273.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,916,320 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $83.16 to $84.135, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 07, 2020 Filed May 11, 2020 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 17,582 | $82.57 | $1,451,735.19 |
DisclosureSEC source: 0001628280-20-007510 · wf-form4_158923711015273.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,958,213 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $82.16 to $83.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 07, 2020 Filed May 11, 2020 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,400 | $81.82 | $441,830.16 |
DisclosureSEC source: 0001628280-20-007510 · wf-form4_158923711015273.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,975,795 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $81.16 to $82.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 07, 2020 Filed May 11, 2020 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 1,762 | $4.18 | $7,365.16 |
DisclosureSEC source: 0001628280-20-007510 · wf-form4_158923711015273.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,981,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2020 Filed May 6, 2020 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 2,400 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-20-006741 · wf-form4_158880358260549.xml · derivative · entry 18 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 849,017 Underlying: COMMON STOCK · 2,400 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| May 06, 2020 Filed May 6, 2020 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 35,300 | $82.26 | $2,903,657.98 |
DisclosureSEC source: 0001628280-20-006741 · wf-form4_158880358260549.xml · nonDerivative · entry 14 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,979,433 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $82.03 to $82.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 06, 2020 Filed May 6, 2020 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 22,298 | $81.35 | $1,813,882.10 |
DisclosureSEC source: 0001628280-20-006741 · wf-form4_158880358260549.xml · nonDerivative · entry 13 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,014,733 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $81.005 to $82.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 06, 2020 Filed May 6, 2020 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 42,402 | $80.33 | $3,406,118.74 |
DisclosureSEC source: 0001628280-20-006741 · wf-form4_158880358260549.xml · nonDerivative · entry 12 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,037,031 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $80.00 to $80.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 06, 2020 Filed May 6, 2020 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 2,400 | $4.18 | $10,032.00 |
DisclosureSEC source: 0001628280-20-006741 · wf-form4_158880358260549.xml · nonDerivative · entry 11 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,079,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 6, 2020 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 2,800 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-20-006741 · wf-form4_158880358260549.xml · derivative · entry 17 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 851,417 Underlying: COMMON STOCK · 2,800 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| May 05, 2020 Filed May 6, 2020 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 20,153 | $80.19 | $1,616,129.53 |
DisclosureSEC source: 0001628280-20-006741 · wf-form4_158880358260549.xml · nonDerivative · entry 10 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,077,033 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $80.00 to $80.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 05, 2020 Filed May 6, 2020 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 724 | $78.25 | $56,650.83 |
DisclosureSEC source: 0001628280-20-006741 · wf-form4_158880358260549.xml · nonDerivative · entry 9 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,097,186 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $78.03 to $78.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 05, 2020 Filed May 6, 2020 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,806 | $77.58 | $217,683.59 |
DisclosureSEC source: 0001628280-20-006741 · wf-form4_158880358260549.xml · nonDerivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,097,910 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $77.03 to $77.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 05, 2020 Filed May 6, 2020 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,530 | $76.52 | $117,075.91 |
DisclosureSEC source: 0001628280-20-006741 · wf-form4_158880358260549.xml · nonDerivative · entry 7 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,100,716 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $75.985 to $76.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 05, 2020 Filed May 6, 2020 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,970 | $75.51 | $450,812.01 |
DisclosureSEC source: 0001628280-20-006741 · wf-form4_158880358260549.xml · nonDerivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,102,246 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $74.87 to $75.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 05, 2020 Filed May 6, 2020 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 2,800 | $4.18 | $11,704.00 |
DisclosureSEC source: 0001628280-20-006741 · wf-form4_158880358260549.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,108,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2020 Filed May 6, 2020 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 13,435 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-20-006741 · wf-form4_158880358260549.xml · derivative · entry 16 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 854,217 Underlying: COMMON STOCK · 13,435 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| May 04, 2020 Filed May 6, 2020 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,971 | $74.00 | $293,854.00 |
DisclosureSEC source: 0001628280-20-006741 · wf-form4_158880358260549.xml · nonDerivative · entry 4 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,105,416 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 04, 2020 Filed May 6, 2020 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 45,258 | $73.37 | $3,320,674.50 |
DisclosureSEC source: 0001628280-20-006741 · wf-form4_158880358260549.xml · nonDerivative · entry 3 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,109,387 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $73.00 to $73.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 04, 2020 Filed May 6, 2020 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 14,742 | $72.55 | $1,069,567.48 |
DisclosureSEC source: 0001628280-20-006741 · wf-form4_158880358260549.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,154,645 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $72.00 to $72.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 04, 2020 Filed May 6, 2020 22:20 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 13,435 | $4.18 | $56,158.30 |
DisclosureSEC source: 0001628280-20-006741 · wf-form4_158880358260549.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,169,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2020 Filed Apr 30, 2020 22:09 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 1,040 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-20-006009 · wf-form4_158828456190920.xml · derivative · entry 8 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 867,652 Underlying: COMMON STOCK · 1,040 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| April 29, 2020 Filed Apr 30, 2020 22:09 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,479 | $81.20 | $282,502.11 |
DisclosureSEC source: 0001628280-20-006009 · wf-form4_158828456190920.xml · nonDerivative · entry 5 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,155,952 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $81.03 to $81.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F5 · balance_after: Includes shares previously reported as indirectly held by the Talasaz and Eskandari 2017 Family Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.